Document Detail


Safety and efficacy of isolated limb perfusion in elderly melanoma patients.
MedLine Citation:
PMID:  12464588     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Older patients are assumed to have a higher risk of complications from isolated limb perfusion (ILP). A study was performed evaluating the safety and efficacy of ILP in patients older than 75 years with advanced melanoma of the limbs. METHODS: A total of 218 therapeutic ILPs with melphalan with or without tumor necrosis factor alpha were performed in 202 patients with advanced measurable melanoma and were analyzed retrospectively. Fifty-three patients (28%) were 75 years or older. RESULTS: Complete response rates were 56% for those older than 75 years and 58% for the younger group (P =.79). Locoregional relapse occurred in 56% of the older group versus 51% in the younger group (P =.61). Limb toxicity, systemic toxicity, local complications, and long-term morbidity were similar in both age groups. Perioperative mortality was low, with one procedure-related death in the older group. Older patients stayed in the hospital for a median of 23 days (younger patients, 19 days; P <.01). CONCLUSIONS: ILP results in similar response rates in the elderly with recurrent melanoma, without increased toxicity, complications, or long-term morbidity compared with younger patients. Older age in itself is not a contraindication for ILP.
Authors:
E M Noorda; B C Vrouenraets; O E Nieweg; A N van Geel; A M M Eggermont; B B R Kroon
Related Documents :
16713848 - A retrospective study of functional outcomes after successful replantation versus amput...
6691088 - Low-dose fibrinolytic therapy in hand ischemia.
3408168 - Limb salvage surgery in a district general hospital: factors affecting outcome.
16336398 - Surgical treatment of femoral artery infected false aneurysms in drug abusers.
3544648 - Diclofenac and oxycodone in treatment of postoperative pain: a double-blind trial.
24579858 - Cost-effectiveness of unicompartmental knee arthroplasty, high tibial osteotomy, and ki...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Annals of surgical oncology     Volume:  9     ISSN:  1068-9265     ISO Abbreviation:  Ann. Surg. Oncol.     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2002-12-04     Completed Date:  2003-03-18     Revised Date:  2007-07-18    
Medline Journal Info:
Nlm Unique ID:  9420840     Medline TA:  Ann Surg Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  968-74     Citation Subset:  IM    
Affiliation:
Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. e.noorda@nki.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents, Alkylating / administration & dosage,  adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Chemotherapy, Cancer, Regional Perfusion / adverse effects,  methods*
Disease-Free Survival
Extremities*
Female
Humans
Length of Stay
Linear Models
Male
Melanoma / drug therapy*,  mortality,  pathology
Melphalan / administration & dosage,  adverse effects
Multivariate Analysis
Netherlands / epidemiology
Retrospective Studies
Skin Neoplasms / drug therapy*,  mortality,  pathology
Survival Rate
Tumor Necrosis Factor-alpha / administration & dosage
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Alkylating; 0/Tumor Necrosis Factor-alpha; 148-82-3/Melphalan
Comments/Corrections
Comment In:
Ann Surg Oncol. 2002 Dec;9(10):939-40   [PMID:  12464583 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measu...
Next Document:  Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy...